Amifampridine phosphate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated in lambert-eaton myasthenic syndrome and myasthenia gravis and has 4 investigational indications. 4-Aminopyridine derivative that functions as a potassium channel blocker to increase release of acetylcholine from nerve terminals. It is used to treat congenital myasthenic syndromes. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zenas, 3, 4-DAPP and Firdapse (TN). Its PubChem CID is 9920716.
Amifampridine phosphate
| CAS No | 446254-47-3 |
|---|---|
| Molecular Formula | C5H10N3O4P |
| Molecular Weight | 207.12 g/mol |
| Synonyms | phosphoric acid;pyridine-3,4-diamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Amifampridine phosphate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated in lambert-eaton myasthenic syndrome and myasthenia gravis and has 4 investigational indications.
The listed CAS number is 446254-47-3.
The listed molecular formula is C5H10N3O4P.
The listed molecular weight is 207.12 g/mol.
phosphoric acid;pyridine-3,4-diamine.
The source lists Zenas, 3, 4-DAPP and Firdapse (TN).